ALEXION PHARMACEUTICALS, INC.

(ALXN)
SummaryQuotesChartsNewsRatingsCompany 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Alexion Pharmaceuticals, Inc. completed the acquisition of remaining majority stake in Caelum Biosciences, Inc. from Fortress Biotech, Inc. and others.

10/05/2021 EDT

Alexion Pharmaceuticals, Inc. agreed to acquire Caelum Biosciences, Inc. from Fortress Biotech, Inc. (NasdaqCM:FBIO) and others for $500 million on September 28, 2021. Upon closing, Alexion will pay Caelum the agreed option exercise price of approximately $150 million, with the potential for additional payments of up to $350 million upon achievement of regulatory and commercial milestones. The transaction is expected to close on October 5, 2021. Mark McElreath and James Sullivan of Alston & Bird LLP acted as the legal advisors to Caelum Biosciences. Alexion Pharmaceuticals, Inc. completed the acquisition of Caelum Biosciences, Inc. from Fortress Biotech, Inc. (NasdaqCM:FBIO) and others on October 5, 2021. The additional payment of $350 million includes: $75 million upon Biologics License Application approval of CAEL-101, $50 million upon CAEL-101 attaining $250 million in annual net sales; $50 million upon CAEL-101 attaining $500 million in annual net sales; $75 million upon CAEL-101 attaining $750 million in annual net sales; and $100 million upon CAEL-101 attaining $1 billion in annual net sales.


© S&P Capital IQ 2021
All news about ALEXION PHARMACEUTICALS, INC.
05/05Ultomiris met primary endpoint in CHAMPION-NMOSD Phase III trial in adults with neuromy..
AQ
04/28Ultomiris approved in the US for adults with generalised myasthenia gravis
AQ
04/26BREAKING PMPRB NEWS : Another Win For Patients And The Innovative Pharmaceutical Industry
AQ
04/11PMPRB UPDATE : PMPRB Is Accepting Intervener Leave Applications For SOLIRIS Re-hearing
AQ
03/31SCC Leave Denied In Alexion Pharmaceuticals Inc v Canada (Attorney General)
AQ
03/29PMPRB UPDATE : Supreme Court Refuses To Hear Appeal From Decision Restricting Canada's Pat..
AQ
03/18Chugai Pharmaceutical Co., Ltd. - Notice of the Settlement of Patent Infringement Litig..
AQ
03/17AstraZeneca reaches settlement agreement resolving patent litigation related to Ultomir..
AQ
03/01AstraZeneca and Neurimmune close exclusive global collaboration and licence agreement t..
AQ
03/01Alexion, Astrazeneca's Rare Disease Group and Neurimmune Closes Deal for Commercializin..
CI
More news
Analyst Recommendations on ALEXION PHARMACEUTICALS, INC.
More recommendations
Chart ALEXION PHARMACEUTICALS, INC.
Duration : Period :
Alexion Pharmaceuticals, Inc. Technical Analysis Chart | ALXN | US0153511094 | MarketScreener
Managers and Directors
George Llado Chief Information Officer & Senior Vice President
Indrani M. Franchini Chief Compliance Officer & Executive VP
Rana Strellis SVP-Global Culture & Social Responsibility
Gianluca Pirozzi Head-Clinical Development, Hematology & Nephrology
Uzair Qadeer Chief Diversity Officer & Senior Vice President
Sector and Competitors